» Articles » PMID: 38856963

Establishment of a Scoring Model for Predicting Clinical Outcomes in Patients with Unilateral Primary Aldosteronism After Superselective Adrenal Artery Embolization

Overview
Journal Ir J Med Sci
Specialty General Medicine
Date 2024 Jun 10
PMID 38856963
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Superselective adrenal arterial embolization (SAAE) is a potential alternative treatment for patients with unilateral primary aldosteronism (PA) who refuse unilateral adrenalectomy. Therefore, we aimed to establish a scoring model to differentiate between hypertensive remission after SAAE.

Methods: This prospective cohort study involved 240 patients who underwent SAAE for unilateral PA. Patients were randomly divided into a model training set and a validation set at a ratio of 7:3. The clinical outcome was a response to hypertension remission, defined as complete, partial, or absent success at 6 months after SAAE. Multivariate logistic regression was performed to identify independent parameters and develop a nomogram to predict clinical outcomes after SAAE. The discrimination, calibration efficacy, and clinical utility of the predictive model were assessed.

Results: Five independent predictors were identified: female sex, duration of hypertension, defined daily dose of antihypertensive medication, diabetes, and target organ damage. The above five independent predictors were put into a predictive model that was presented as a nomogram. Using bootstrapping for internal validation, the C-statistic for the predictive model was 0.866 (95% confidence interval [CI]: 0.834 to 0.898). In the validation cohort, the area under the curve (AUC) of the nomogram for predicting hypertension remission after SAAE was 0.809.

Conclusion: The present model is the first nomogram-based score that specifically predicts hypertension remission after SAAE in patients with unilateral PA using conventional parameters. This is an effective risk stratification tool that can be used by clinicians for timely and tailored preoperative risk discussions.

Citing Articles

Exploration of the shared gene signatures and comorbidity mechanisms of primary aldosteronism and atrial fibrillation.

Wan J, Liu S, Luo T, Yang Y, Wang D, Wang X Endocr Connect. 2024; 14(1.

PMID: 39475718 PMC: 11728919. DOI: 10.1530/EC-24-0402.

References
1.
Turcu A, Yang J, Vaidya A . Primary aldosteronism - a multidimensional syndrome. Nat Rev Endocrinol. 2022; 18(11):665-682. DOI: 10.1038/s41574-022-00730-2. View

2.
Naito T, Inoue K, Sonehara K, Baba R, Kodama T, Otagaki Y . Genetic Risk of Primary Aldosteronism and Its Contribution to Hypertension: A Cross-Ancestry Meta-Analysis of Genome-Wide Association Studies. Circulation. 2023; 147(14):1097-1109. PMC: 10063185. DOI: 10.1161/CIRCULATIONAHA.122.062349. View

3.
Funder J, Carey R . Primary Aldosteronism: Where Are We Now? Where to From Here?. Hypertension. 2022; 79(4):726-735. DOI: 10.1161/HYPERTENSIONAHA.121.18761. View

4.
Mulatero P, Monticone S, Deinum J, Amar L, Prejbisz A, Zennaro M . Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. J Hypertens. 2020; 38(10):1919-1928. DOI: 10.1097/HJH.0000000000002510. View

5.
Cohen J, Bancos I, Brown J, Sarathy H, Turcu A, Cohen D . Primary Aldosteronism and the Role of Mineralocorticoid Receptor Antagonists for the Heart and Kidneys. Annu Rev Med. 2022; 74:217-230. PMC: 9892285. DOI: 10.1146/annurev-med-042921-100438. View